SCHEMBL19258224

SCHEMBL19258224

CC1c2ccccc2CN(C)C1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 6/20 0.43
SLC6A4 P31645 6/20 0.43
SLC6A3 Q01959 6/20 0.43
OPRM1 P35372 3/20 0.42
TDP1 Q9NUW8 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
THRB P10828 1/20 0.40
ALOX15 P16050 1/20 0.40
APEX1 P27695 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PRCP P42785 1/20 0.40
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11997024 0.79 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL10278431 0.79 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL18559580 0.79 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL19901373 0.78 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL15679224 0.78 SLC6A2 (0.50) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL21400411 0.75 KDM4E (0.41) SLC6A2SLC6A4SLC6A3TDP1KDM4E
SCHEMBL13052406 0.74 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL19139967 0.73 PRCP (0.41) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL18750475 0.73 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3OPRM1TDP1
SCHEMBL17752295 0.73 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3OPRM1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200237755-A1 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-07-30 US disclosed
US-RE48059-E1 Piperazine-substituted benzothiophenes for treatment of mental disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-06-23 US disclosed
US-20170231983-A1 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200237755-A1 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders GRIN2C, TPH1, HTR2C SLC6A2 94/4885SLC6A4 41/4885SLC6A3 27/4885
US-20170231983-A1 Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders GRIN2C, TPH1, HTR2C SLC6A2 94/4885SLC6A4 41/4885SLC6A3 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.